Drug Profile


Alternative Names: JNJ-26866138; LDP-341; MG-341; MLN-341; NSC-681239; PS 0341; PS-341; Velcade

Latest Information Update: 18 Apr 2017

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Dana-Farber Cancer Institute; Duke University; Erasmus MC; Genentech; Hoosier Cancer Research Network; HOVON Foundation; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag; Johnson & Johnson; Millennium; Millennium Pharmaceuticals; Takeda Oncology; Weill Cornell Medical College
  • Class Antineoplastics; Antirheumatics; Boronic acids; Pyrazines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mantle-cell lymphoma; Multiple myeloma
  • Registered B cell lymphoma
  • Phase III Diffuse large B cell lymphoma
  • Phase II Acute lymphoblastic leukaemia; Glioma; Graft-versus-host disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Phase I/II Waldenstrom's macroglobulinaemia
  • Phase I Hodgkin's disease; Malignant melanoma
  • Preregistration Submission Withdrawal Follicular lymphoma
  • No development reported Pancreatic cancer
  • Discontinued Adenocarcinoma; Amyloid light-chain amyloidosis; Cerebral ischaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Non-small cell lung cancer; Prostate cancer; Rheumatoid arthritis; T cell prolymphocytic leukaemia

Most Recent Events

  • 18 Jan 2017 M.D. Anderson Cancer Center completes a phase II trial in Myelodysplastic syndromes in USA (SC) (NCT01891968)
  • 06 Dec 2016 Janssen-Cilag terminates the OPTIMIZED-RETREAT trial in Multiple myeloma (Combination therapy) in Belgium, Finland, France, Germany, Israel, Italy, Norway, Poland, Portugal, Sweden, Turkey and in the Netherlands because of insufficient sample size as per results
  • 03 Dec 2016 Final adverse events and efficacy data from a phase III trial in Multiple myeloma presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top